Novartis: new positive CHMP opinion for Cosentyx
(CercleFinance.com) - Novartis announced on Friday that it has received a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency on its application for marketing authorisation for a paediatric version of Cosentyx, its treatment for psoriasis.
In April the CHMP already recommended that Cosentyx be approved for the treatment of adult patients with active non-radiographic axial spondyloarthritis, a disease characterised by chronic inflammatory back pain.
Novartis says it is seeking approval of Cosentyx, a new type of immunosuppressant, in 10 different indications over the next 10 years.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
In April the CHMP already recommended that Cosentyx be approved for the treatment of adult patients with active non-radiographic axial spondyloarthritis, a disease characterised by chronic inflammatory back pain.
Novartis says it is seeking approval of Cosentyx, a new type of immunosuppressant, in 10 different indications over the next 10 years.
Copyright (c) 2020 CercleFinance.com. All rights reserved.